WHC is still in active development. Read this to understand our approach.
depiction of ICXJGCSEMJXNQF-UHFFFAOYSA-N.svg
isomerdesign

GSK-1360707F

Verificar en isomerdesign

drugmap

GSK-1360707

Verificar en drugmap

drugmap

GSK-1360707

Verificar en drugmap

wiki

GSK1360707F

Verificar en wiki

Data

InChI: InChI=1S/C14H17Cl2NO/c1-18-9-13-7-14(13,4-5-17-8-13)10-2-3-11(15)12(16)6-10/h2-3,6,17H,4-5,7-9H2,1H3

Sinónimos: rel-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane, 1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX), BDBM50322698,1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX), CHEMBL1173532, Serotonin/dopamine/norepinephrine reuptake inhibitors (depression), GlaxoSmithKline,Monoamine reuptake inhibitors (depression), GlaxoSmithKline,GSK-1360707F,SCHEMBL3194096

Estimated data

Solubilidad: -3.009 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 55.3% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.